GYN: Ovarian, Fallopian, Peritoneal Cancer Clinical Trials

Showing 1-16 of 16 items
1.
  • Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer
  • This is a two-part multicenter, randomized, double-blind, placebo-controlled, Phase II/III study of maintenance Vigil™ Ovarian (gemogenovatucel-T) (formerly known as FANG™) in women with Stages III/IV high-grade serous / endometrioid ovarian, fallopian tube or primary peritoneal cancer. Eligibility criteria are identical for both Part 1 and Part 2 of the study. Subjects will have had a minimum of 4 and a maximum of 12 doses of Vigil™ prepared and stored from ovarian tumor cells obtained at the time of primary surgical debulking or initial diagnostic / evaluative laparoscopy (tissue for immunotherapy manufacture must be procured prior to initiation of neoadjuvant chemotherapy). An equal number of placebo doses will manufactured. Subjects will have achieved a clinically defined complete response following primary surgery and adjuvant chemotherapy.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
2.
3.
4.
5.
6.
  • Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
  • This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs. Phase I studies also try to define the appropriate dose of the investigational combination to use for further studies. "Investigational" means that the combination of these drugs is still being studied and that research doctors are trying to find out more about it. It also means that the FDA has not approved either of these drugs nor the combination of being tested for use in patients, including people with your type of cancer. BKM120, BYL719 and olaparib are drugs that may stop cancer cells from growing abnormally. These drugs when combined in laboratory experiments with animals, have demonstrated anti-cancer activity. Information from these other research studies suggests that the following agents BKM120, BYL719 and olaparib, may help to shrink tumor cells in the types of cancers being studied in this research study. In this research study, the investigators are looking for the highest dose that can be given safely and also to see if the combination of BKM120 or BYL719 and olaparib is effective in treating your type of cancer.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
7.
9.
10.
11.
12.
13.
  • A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens
  • This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received at least three previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by Eastern Cooperative Oncology Group performance status (ECOG). Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values.
  • Diagnoses: GYN: Ovarian, Fallopian, Peritoneal Cancer
  • Status: Recruiting
14.
15.
16.
Showing 1-16 of 16 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms